

## Review Article

# A Review of the *GSTM1* Null Genotype Modifies the Association between Air Pollutant Exposure and Health Problems

Dwi Aris Agung Nugrahaningsih <sup>1</sup>, Hevi Wihadmadyatami,<sup>2</sup> Sitarina Widyarini,<sup>3</sup> and Rahmi Ayu Wijayaningsih<sup>4</sup>

<sup>1</sup>Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

<sup>2</sup>Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

<sup>3</sup>Department of Pathology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

<sup>4</sup>Master of Biomedical Science Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

Correspondence should be addressed to Dwi Aris Agung Nugrahaningsih; [dwi.aris.a@ugm.ac.id](mailto:dwi.aris.a@ugm.ac.id)

Received 3 October 2022; Revised 17 January 2023; Accepted 19 January 2023; Published 6 February 2023

Academic Editor: Paulo M. Pinto

Copyright © 2023 Dwi Aris Agung Nugrahaningsih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Air pollution is one of the significant environmental risks known as the cause of premature deaths. It has deleterious effects on human health, including deteriorating respiratory, cardiovascular, nervous, and endocrine functions. Exposure to air pollution stimulates reactive oxygen species (ROS) production in the body, which can further cause oxidative stress. Antioxidant enzymes, such as glutathione S-transferase mu 1 (*GSTM1*), are essential to prevent oxidative stress development by neutralizing excess oxidants. When the antioxidant enzyme function is lacking, ROS can accumulate and, thus, cause oxidative stress. Genetic variation studies from different countries show that *GSTM1* null genotype dominates the *GSTM1* genotype in the population. However, the impact of the *GSTM1* null genotype in modifying the association between air pollution and health problem is not yet clear. This study will elaborate on *GSTM1*'s null genotype role in modifying the relationship between air pollution and health problems.

## 1. Introduction

Air pollution is a process to release pollutants into the air. Air pollutant varies significantly in the different places depending on the source of the pollution. Generally, air pollutant consists of several compounds including gaseous and particulate pollutants. Particulate pollutant or particulate matter (PM) is considered as one of the main components of a deleterious effect on health [1]. PMs could enter the tissue in the body after being inhaled, mainly due to their small size [2]. They can elicit the formation of reactive oxygen species (ROS) and, consequently, induce antioxidant enzymes expression [3]. The imbalance between ROS production and the availability of antioxidant enzymes may cause tissue damage that plays an essential

role in the development of environment induced health deterioration [4].

The increase of ROS formation will stimulate antioxidant enzymes, including phase I and II metabolic enzymes [5, 6]. Glutathione S-transferases (GST), a large family of phase II enzymes, is one of the crucial enzymes modifying oxidative stress, which includes the glutathione S-transferase mu 1 (*GSTM1*), glutathione S-transferase theta 1 (*GSTT1*), and glutathione S-transferase pi 1 (*GSTP1*) classes. They provide protection toward air pollution deleterious effect. Studies have shown that genetic variation of the enzymes is associated with several air pollution diseases [7].

There are some genetic variations in GST enzymes encoding genes. One of the most common variations in the GST gene is the *GSTM1* null genotype, resulting in partial or




FIGURE 1: Particles from the air captured using filter nylon membrane  $0.2 \mu\text{m}$  and examined using SEM. Some particles have a diameter of  $<10 \mu\text{m}$ .




FIGURE 2: PM deposition along the airway. Coarse particles ( $\text{PM}_{10}$ ) and fine particles are deposited more on upper airways, cleared by the mucociliary system, and transferred into lymph nodes. Ultra-fine particles can reach alveoli, and enter blood circulation through several mechanism including phagocytosis by macrophages, endocytosis by alveolar epithelial cells and endothelial cells, passive diffusion into blood circulation, active or passive transportation through pore in cytoplasm of endothelial cells, and gaps between epithelial cells.

complete loss of enzyme activity. The deletion of the *GSTM1* encoding gene is often related to poor health outcomes related to air pollutant exposure [8, 9]. In this study, we will do a review of *GSTM1* in correlation with air pollution-induced diseases.

## 2. Air Pollutant

Air pollutants consist of a mixture of gaseous and PM, which varies in each area depending on the source of the pollution, the wind, and sunlight. The gaseous components of air pollution mainly are carbon monoxide (CO), nitrogen oxide (NO), nitrogen dioxide ( $\text{NO}_2$ ), ground-level ozone ( $\text{O}_3$ ), and sulphur dioxide ( $\text{SO}_2$ ) [10]. PM of the air pollutant consists of solid particle and liquid droplets. Based on their size, PMs are divided into three types, such as  $\text{PM}_{10}$  ( $\text{PM}_{10}$ ),  $\text{PM}_{2.5}$  ( $\text{PM}_{2.5}$ ), and  $\text{PM}_{0.1}$  ( $\text{PM}_{0.1}$ ).  $\text{PM}_{10}$  or coarse particles are particles in the air with diameters  $10 \mu\text{m}$  and less,  $\text{PM}_{2.5}$  or fine particles are particles in the air with a diameter of  $2.5 \mu\text{m}$  and less, and  $\text{PM}_{0.1}$  or ultrafine particles are particles in the air with a diameter of  $0.1 \mu\text{m}$  and more diminutive

[11, 12]. Figure 1 shows particles observed by scanning electron microscopy (SEM) of PM with diameter  $<10 \mu\text{m}$ .

The size of the PM will affect their ability to penetrate the human body. Coarse materials are unable to enter the small airways and alveoli. Meanwhile, fine and ultrafine particles can enter small airways and alveoli and reach systemic circulation after penetrating the air–blood barriers [3, 13]. Figure 2 illustrates the deposition of  $\text{PM}_{10}$ ,  $\text{PM}_{2.5}$ , and  $\text{PM}_{0.1}$  in the airway, the mechanism of clearance from the air way, and the absorption into the systemic circulation.

## 3. Air Pollutant Impact on Human Body

Based on World Health Organization estimation, exposure to air pollutants causes approximately 1 out of 10 deaths worldwide [14]. After entering the body, air pollutants, including PM, can stimulate inflammation-related agents, induce cytokines expression, trigger oxidative stress, change genes expression, and induce epigenetic changes [15]. Epigenetics changes, such as deoxyribonucleic acid (DNA) methylation may act as a mediator in the development of adverse

TABLE 1: Example of ROS and RNS radicals and non-radicals oxidants.

Reactive oxygen species (ROS)	Radicals oxidants: superoxide ( $O_2^-$ ), hydroxyl radical ( $OH^\cdot$ ), and hydroxyperoxyl ( $H_2O_2^\cdot$ )	Non-radicals oxidants: hydrogen peroxide ( $H_2O_2$ ), ozone ( $O_3$ ), and organic peroxide (ROOH)
Reactive nitrogen species (RNS)	Radicals oxidants: nitric oxide ( $NO^\cdot$ ) and nitrogen dioxide ( $NO_2^\cdot$ )	Non-radical oxidants: nitrous acid ( $HNO_2$ ), peroxyxynitrite ( $ONOO^-$ ), and dinitrogen trioxide ( $N_2O_3$ )

health outcome due to PM exposure [16–18]. After entering the airway, PM increases pulmonary neutrophils, stimulates alveolar macrophage and airway epithelial cells to produce pro-inflammatory mediators, such as interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin 1 beta (IL-1 $\beta$ ), interleukin-4 (IL-4), tumor necrosis factor alpha (TNF- $\alpha$ ), and transforming growth factor beta 1 (TGF- $\beta$ 1), which leads to local inflammation in the lung, oxidative stress, and also systemic inflammation manifesting as the increase of circulating fibrinogen, systemic IL-1 $\beta$ , IL-6, and TNF- $\alpha$  concentration [19–22].

Studies have revealed the association of PM with several diseases, from the disease of the respiratory system, which is in direct contact with PM, to the disease of the endocrine system, which is not in direct contact with PM. Respiratory system problem is the most expected system affected by PM exposure. Long- and short-term exposure to PM is related to several disease of respiratory system, such as asthma, chronic obstructive pulmonary disease, and lung cancer [23]. Short- and long-term exposure to elevated PM<sub>2.5</sub> levels is associated with several cardiovascular problems, such as ischemic heart disease, heart failure, and cerebrovascular disease [24–27]. Surveys conducted between 1989 and 2012 showed that PM exposure is associated with changes of atrioventricular conduction, increase of cardiovascular disease markers, and development of heart disease [20, 24, 28–31]. Exposure to PM<sub>2.5</sub> is associated with Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia, and cognitive decline [32–34]. A study in mice revealed that chronic inhalation of PM-induced oxidative stress and inflammation in the brain, increase perineuronal nets, and decrease interneurons number, which suggest PM contribution in the development of central nervous system dysfunction [35]. Furthermore, exposure to PM<sub>2.5</sub> and NO<sub>2</sub> in children correlates with a higher body mass index, and development of type 2 diabetes mellitus (type 2DM) by disturbing insulin sensitivity and  $\beta$ -cell function [36]. Exposure to PM<sub>2.5</sub> might reduce metabolic insulin sensitivity [37]. Meta-analysis study to assess the association of PM<sub>2.5</sub> exposure with type 2DM showed that long-term exposure to PM<sub>2.5</sub> increases the risk of type 2 DM development [38, 39].

The length of exposure to PM affects the severity of body function disturbance. Short-term exposure to air pollution showed lower association with magnitude than long-term exposure. Long-term exposure of PM is associated with stronger systemic inflammatory marker expression than short term-exposure [22, 40]. Study in Korea showed that long-term exposure to PM<sub>10</sub> was related to ischemic heart disease, but short-term exposure was not [41]. Longer duration of PM<sub>2.5</sub> exposure also related to higher blood pressure [42]. *In vitro* study also showed that repeated exposure to PM<sub>2.5</sub> to Beas-2B, normal bronchial epithelium cells, result

in the increased sensitivity and magnitude of change of several genes associated with airway disorders [43].

#### 4. Mechanism of PM Deleterious Effect to the Body

There are three hypothetical mechanisms of PM’s deleterious effect on the body. The first hypothesis is that exposure of PM into the airway will elicit oxidative stress followed by lung inflammation, leading to systemic inflammation, and induce subsequent effects, such as cardiovascular inflammation, endothelial dysfunction, platelet aggregation, and vasoconstriction, which will lead to the development of multi-organ system problems. The second hypothesis is that the exposure of PM into the airway will stimulate the lung’s sensory receptor, resulting in the imbalance of the autonomic nervous system, which favors sympathetic signals, leading to the increase of arrhythmia potential, an increase in heart rate and vasoconstriction. The last hypothesis suggests that the PM is translocated from the lung to the systemic circulation and directly affecting the cell by inducing systemic oxidative stress and subsequent systemic inflammation [23]. Exposure to PM<sub>2.5</sub> is associated with increase inflammatory response, endothelial apoptosis, and antiangiogenic parameter expression, which could contribute to the development of atherosclerosis [44].

Oxidative stress and inflammation are two central mechanisms of PM deleterious effects to the body. *In vitro* study has revealed that alveolar macrophage isolated from humans and rats respond to PM stimulation by generating oxidants, which happens within minutes to an hour after stimulation. Meanwhile, cytokines production needs hours after PM stimulation, but the microbial origin PM can directly induces cytokines production by alveolar macrophage [45]. It is unclear which one happens first. Anyhow, oxidative stress and inflammation are related mechanisms where one phenomenon’s increase will affect others [46].

#### 5. PM Induces Oxidative Stress

Oxidative stress is a condition where there is an imbalance between oxidants generation and antioxidant capacity. *Oxidant* is molecules that receive electron during reductive oxidative reactions and enhances oxidation on target molecules. There are various biological oxidants, including ROS and reactive nitrogen species (RNS). Both consist of radicals and non-radicals oxidants. Radicals, molecules containing at least one electron, are more reactive and unstable compared with non-radicals oxidants. However, non-radicals oxidants also can be easily converted into radicals oxidants. Table 1 shows radicals and non-radicals oxidants [47, 48].




FIGURE 3: Correlation between air pollution, oxidative stress, and diseases. ROS, reactive oxygen species; RNS, reactive nitrogen species;  $ONOO^-$ , peroxynitrite;  $HO^-$ , hydroxyl ion;  $NO$ , nitric oxide;  $O_2^-$  superoxide anion;  $H_2O_2$ , hydrogen peroxide.

Oxidants in a biological system that causes oxidative stress can be produced endogenously during biological processes and also induced exogenously due to exposure to oxidant production inducers, such as pesticide, drugs, ultraviolet light, X-ray, heavy metal, and air pollutant, including PMs [47].

Various components of PM can cause ROS and RNS generation, which leads to oxidative stress. Exposure to  $PM_{2.5}$  could cause mitochondrial damage and ROS production, which leads to cell death [49]. Exposure to  $PM_{2.5}$  in pregnant women showed positive association with placental 3-nitrotyrosine, the biomarker of nitrogen free radicals species [50]. Polycyclic aromatic hydrocarbons (PAHs), one of the PM components, generate ROS during catalytic conversion by cytochrome P450 1A1, which converts PAHs to quinones [51]. Diesel exhaust particle (DEP) components induce bioactivation by P450 reductase and generate ROS during the process. Microglia can engulf DEP entering the body and cause superoxide production. Study on alveolar epithelial cells showed that PM exposure could induce the generation of iron-derived free radicals, which can cause mitochondrial dysfunction [42, 52, 53].

As a response to the abundant production of ROS and RNS due to PM exposure, the body increase the production of various antioxidants, including antioxidant enzymes. This mechanism aims to maintain cellular redox equilibrium for preventing cellular injuries. However, the antioxidant defenses might not be enough when the production of ROS is chronic or the amount of exposure is enormous. When ROS production is higher and faster than antioxidant production, oxidative stress occurs [16]. Long-term expo-

sure to oxidative stress can cause protein, lipid, and DNA, which lead to cell aging, and cell death that is important in the development of several disease, such as cancer, atherosclerosis, AD, DM, and its complications [54]. The interaction of superoxide radicals and nitrogen oxides can form peroxynitrite ( $ONOO^-$ ). The build-up of RNS can cause nitrosative stress, which is related to several diseases. Peroxynitrite ( $ONOO^-$ ) has a substantial and long-lived oxidant effect that can cause damage to DNA, membrane lipids, and protein, causing inflammation and cell death related to the initiation, progression, and severity of diseases [53–55]. Figure 3 presents the correlation between air pollution and disease development.

## 6. Endogenous Antioxidants Mechanism in Oxidative Stress

Antioxidants defense mechanisms are available throughout the body, including in bronchial lining fluid for protecting the body from the deleterious effect of PM. There are two kinds of antioxidants, synthesized and ingested antioxidants. The body could produce antioxidants in the form of protein, enzymes, and low molecular weight scavengers. Antioxidant proteins include superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, heme oxygenase-1, glutathione (GSH), and antioxidant enzymes [55]. Antioxidant enzymes include phase 1 and phase 2 metabolic enzymes. GST is one of the important phase II enzymes involved in detoxifying xenobiotics, including drugs and toxicants [56].

According to the location, GSTs in mammals consist of three families, namely cytosolic GSTs, mitochondrial GSTs,

and microsomal GSTs. Microsomal GSTs are important for eicosanoids and GSH. Therefore, they are referred as membrane-associated proteins in eicosanoid and glutathione metabolism [57]. Cytosolic GSTs are more involved in the detoxification process than mitochondrial and microsomal GSTs. Cytosolic GST includes seven classes, which are classified based on their amino acid sequences. The seven classes are alpha ( $\alpha$ , GSTA), mu ( $\mu$ , GSTM), pi ( $\pi$ , GSTP), sigma ( $\sigma$ , GSTS), theta ( $\theta$ , GSTT), omega ( $\omega$ , GSTO), and zeta ( $\xi$ , GSTZ) [58]. Isoenzymes from the same class sharing more than 40% identity, and isoenzymes from different classes sharing less than 25% identity [49].

Exposure to PM could induce the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), important regulator of cellular resistance toward oxidants, which subsequently leading to increased expression of antioxidants, including GSTs [59]. During oxidative stress, ROS will disrupt transcription factor Nrf2 binding to its negative regulator, Kelch-like enoyl-CoA hydratase-associated protein 1, in the cytoplasm leading to Nrf2 translocation into the nucleus, which subsequently activates antioxidant response element and induces the transcription of several antioxidants including GSTs [60]. The expression of GSTs will help to metabolize the harmful xenobiotics into less harmful metabolites [61]. They also can conjugate GSH into a wide range of molecules, including hydrophobic and electrophilic molecules, for detoxifying them into less harmful substances and easier to be excreted out of the body [56].

## 7. Genetic Variation of Cytosolic GST

Different genes in the chromosome are responsible for different classes of cytosolic GST enzymes. They are GSTA, GSTM, GSTP, GSTS, GSTT, GSTZ, and GSTO [62]. Some of the genes encoded GST enzymes are polymorphic, resulting in the enzymes' different activity and responses to xenobiotics exposure [63]. One of the most common GSTs polymorphisms examined is GSTM1 polymorphism. GSTM1 is part of five highly similar tandem GSTM genes, namely GSTM1, GSTM2, GSTM3, GSTM4, and GSTM5 on chromosome 1 [64]. There are several polymorphisms of GSTM. However, variation of GSTM1, especially deletion of GSTM1, is the most dominant variation among all variations of GSTM1.

Deletion of the GSTM1 gene, or GSTM1 null genotype, is highly prevalent in the population [65]. Study on Caucasian population from North America and Europe showed that the GSTM1 null genotype frequency was 53.1%. Great Britain and Portugal had higher GSTM1 null genotype frequency, but it was not significantly different from the rest of Caucasian population in North America and Europe. The GSTM1 null genotype frequency in African and African American is 52.9%. Interestingly other studies showed that the frequency of GSTM1 null genotype varies among African countries. The frequency of GSTM1 null genotype in Egypt is 55.5%, Nigeria is 30%, Namibia is 11.2%, Cameroon is 27.8%, and Somalia is 40%. Asian population also shows difference of GSTM1 null genotype frequency. The prevalence of GSTM1 null genotype in Japan is 47.6%, in Korea is

52.1%, in Singapore is 56.2%, in Philippines is 51.7%, in India is 29.6%, in Afghanistan is 46%, and in Iran is 40.6% [66]. Our study conducted in Central Java, Indonesia showed that the prevalence of the GSTM1 null genotype among Javanese is 82.1% [67]. In unrelated subjects in Iran, the prevalence of GSTM1 null genotype is 43.8–56% [68]. Lack of GSTM1 enzymes is known to be associated with certain diseases.

## 8. GSTM1 Null Genotype and PM-Related Disease

GSTM1, as one of the essential enzymes from the GSTs family, also have an essential role in the detoxification of several toxicants from the environment, such as benzo[ $\alpha$ ]pyrene, nitrosamine, and aromatic amines, which also exist as PM in the air [69]. Variation of GSTs, including the GSTM1 null genotype, have been shown to modify the body response to air pollutant exposure [70].

**8.1. Respiratory System.** Studies regarding the effect of GSTM1 absence on air pollutant-induced respiratory system—disturbance shows contradicting results. Table 2 shows studies about the effect of GSTM1 null genotype on respiratory system.

The most common air pollutant studied was ozone, followed by PM. Studies with many participants, Castro-Giner et al. [87]; Curjuric et al. [79]; and Hersoug et al. [77] showed that GSTM1 deletion did not modify the effect of air pollutant exposure on respiratory system related parameters. However, most of above mentioned studies show that GSTM1 deletion does modify the effect of air pollutant exposure to respiratory system. Interestingly, administration of antioxidants, such as vitamins C and E above the minimum daily recommended dose might compensate for this genetic susceptibility [78]. Administration of antioxidant agents can prevent the problem of respiratory system related to air pollutant exposure.

**8.2. Cardiovascular System.** After entering the lung, PM induce cytokines and other inflammatory factors, which consequently cause local lung inflammation and further cause systemic inflammation. This condition is often related to the increased of cardiovascular disease [88–90]. Several studies revealed the effect of GSTM1 null genotype in modifying air pollutants, especially PM, association with cardiovascular parameters. Table 3 showed a summary of studies that investigate GSTM1 null genotype effect on PM-related cardiovascular parameters.

Among nine studies presented in Table 3, six studies showed that GSTM1 modify the interaction between air pollutant with cardiovascular marker namely heart rate variability, brachial artery dilatation, and soluble vascular cell adhesion molecule (sVCAM-1). Meanwhile, another three studies showed that GSTM1 deletion has no effect on air pollutant correlation with several cardiovascular parameter, blood markers of systemic inflammation, prothrombotic state, oxidative stress, vascular dysfunction, and blood pressure. The increase of cardiovascular disease-related marker

TABLE 2: Studies of the effect of *GSTM1* absence on respiratory system.

No.	Author	Sample number	Pollutant type	Parameters measured	Result
1.	Yang et al. [30]	1180	PM <sub>2.5</sub>	Low respiratory tract infection (LRTI)	<i>In utero</i> exposure to PM <sub>2.5</sub> , especially during the third trimester of pregnancy, is associated with a higher frequency of lower respiratory tract problems at one year, especially in the absence of <i>GSTM1</i> in the mother
2.	Reddy et al. [71]	129	PM <sub>10</sub> , SO <sub>2</sub> , NO <sub>2</sub> , and NO	Percent change in intraday variability of forced expiratory volume 1 (FEV)	Higher exposure to SO <sub>2</sub> associates with more significant FEV1 intraday variability on those with <i>GSTM1</i> deletion  Children with <i>GSTM1</i> positive genotype associate with
3.	Romieu et al. [72]	151	Ozone	Respiratory symptoms and lung function	Asthmatic children with <i>GSTM1</i> null genotype showed increase of reported breathing difficulty associated with ozone exposure
4.	Alexis et al. [73]	35	Ozone	Lung function and inflammation	<i>GSTM1</i> did not modify lung function and granulocyte influx after acute ozone exposure, but <i>GSTM1</i> null genotype person showed a significant increase of airways neutrophils and increase expression of HLA-DR 24 hours after ozone exposure
5.	Framptom et al. [74]	24	Ozone	Pulmonary, systemic vascular function, and cardiac function	There were no consistent effects of ozone exposure with all parameters measured. All the results were not dependent on the <i>GSTM1</i> genotype
6.	Yang et al. [30]	307	Indoor PM <sub>2.5</sub> and environmental tobacco smoke (ETS)	Susceptibility to RTIs	Deletion of <i>GSTM1</i> increases the susceptibility of RTIs associated with prenatal exposure of indoor PM <sub>2.5</sub> and ETS
7.	Kim et al. [75]	59	Ozone	Pulmonary function and subjective symptom	<i>GSTM1</i> genotype alone did not modify ozone induces an increase in neutrophilic inflammation in the airways and decrease of FEV1
8.	Ghosh et al. [76]	793	Second-hand smoke (SHS), polycyclic aromatic hydrocarbons (PAH), and PM <sub>2.5</sub>	Acute bronchitis	<i>GSTM1</i> genotype did not modify the risk to develop acute bronchitis in preschool children after exposure to SHS, PAH, and PM <sub>2.5</sub>
9.	Hersoug et al. [77]	3471	The indoor source of PM	Objective markers of respiratory disease	<i>GSTM1</i> genotype did not modify the change of objective markers of respiratory disease after exposure to the indoor source of PM
10.	Romieu et al. [78]	158	Ozone	Forced expiratory flow	Asthmatic children with <i>GSTM1</i> null genotype were more prone to deleterious effects on airways related to ozone exposure
11.	Curjuric et al. [79]	4365	PM <sub>10</sub>	Lung function	<i>GSTM1</i> genotype did not modify the change of lung function after exposure to PM <sub>10</sub>
12.	Madden et al. [80]	15	Diesel exhaust (DE) and ozone	Lung function	<i>GSTM1</i> genotype did not modify the changes in lung function associated with DE and ozone exposure
13.	Lan et al. [81]	244	Indoor smoky coal emission	Lung cancer	<i>GSTM1</i> null genotype is associated with a higher risk of lung cancer in smoky coal use.
14.	Dey et al. [82]	155	They were non-respirable PM, SO <sub>2</sub> , NO <sub>2</sub> , organic silicone, and aliphatic C-F compounds in the air.	Lung function	<i>GSTM1</i> null genotype modify the changes of lung function in smokers living around coal mines.
15.	Bowatte et al. [83]	620	Traffic-related air pollution (TRAP)	Asthma, wheeze, and hay fever	<i>GSTM1</i> null genotype modifies the risk of asthma and wheeze, but not hay fever related to TRAP exposure during the first year of life

TABLE 2: Continued.

No.	Author	Sample number	Pollutant type	Parameters measured	Result
16.	Chen et al. [84]	210	Ozone	Lung function	<i>GSTM1</i> null/ <i>NQO1</i> Pro187 Pro-combination, but not <i>GSTM1</i> null genotype alone is associated with ozone-related changes in lung function
17.	Bergamaschi et al. [85]	24	Ozone	Lung function and blood parameter	Participants with <i>NQO1</i> WT and <i>GSTM1</i> null show lung function and serum CC16 change associated with ozone level
18.	Dillon et al. [86]	35	Clinical Center Reference Endotoxin (CCRE)	Airway and systemic inflammation parameter	The participant with <i>GSTM1</i> null genotype shows a significant increase of circulating white blood cells, polymorphonuclear neutrophils, platelets, and sputum after the challenge with CCRE
19.	Castro-Giner et al. [87]	2920	Local traffic-related air pollution (estimated NO <sub>2</sub> )	Asthma	<i>GSTM1</i> null genotype did not modify the effect of local traffic-related air pollution exposure with asthma prevalence
20.	Zhang et al. [31]	17	Diesel exhaust (DE) and allergen	Lung function	<i>GSTM1</i> genotype did not modify the change of lung function after exposure to DE or allergen

TABLE 3: Studies about *GSTM1* null genotype effect on air pollutant-induced cardiovascular changes.

No.	Author	Sample number	Pollutant type	Parameters measured	Result
1.	Chahine et al. [91]	539	PM <sub>2.5</sub>	Heart rate variability (HRV): standard deviation normal-to-normal (SDNN), high frequency (HF), and low frequency (LF)	<i>GSTM1</i> modifies the association of PM <sub>2.5</sub> -HRV. In <i>GSTM1</i> null genotype participants, PM <sub>2.5</sub> concentrations negatively modify SDNN, HF, and LF
2.	Meier-Girard et al. [92]	1593: Total, 510 (without cardiovascular morbidity)	TPM <sub>10</sub>	HRV/HRD	There is a strong association between TPM10 and HRV/HRD parameters in participants with <i>GSTM1</i> null genotype
3.	Ren et al. [93]	1000	PM <sub>2.5</sub> and black carbon (BC)	Homocysteine	<i>GSTM1</i> null genotype does not modify adjusted percent change in homocysteine (log) association with interquartile range increases of 7-day moving averages of PM <sub>2.5</sub> and BC
4.	Probst-Hensch et al. [94]	1133	Second-hand smoke (SHS)	SDNN and standard deviation of all normal-to-normal intervals (SDAN)	There is a suggestion for an elevated decrease in SDNN and SDAN among subjects exhibiting <i>GSTM1</i> deletion genotype and high SHS exposure or obesity
5.	Schwartz et al. [70]	2280	PM <sub>2.5</sub>	HF component of HRV	There is a significant association of PM <sub>2.5</sub> and HF in participants with the <i>GSTM1</i> null deletion
6.	Sack et al. [95]	21	Diesel exhaust particle	Brachial artery diameter (bad)	Participants with <i>GSTM1</i> null genotype showed more significant vasoconstriction of bad after DE exposure than subjects with the wild-type allele
7.	Madrigano et al. [29]	809	BC	Soluble intercellular adhesion molecule (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM-1)	They found evidence for differential effects of BC exposure on the change of % sVCAM-1 by <i>GSTM1</i> status
8.	Balmes et al. [96]	87	Ozone	Blood markers of systemic inflammation, prothrombotic state, oxidative stress, and vascular dysfunction	<i>GSTM1</i> did not modify the interaction between ozone and systemic inflammation, oxidative stress, and endothelial dysfunction marker
9.	Mordukhovich et al. [97]	457	BC	Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	<i>GSTM1</i> null genotype did not modify the interaction between BC and blood pressure

TABLE 4: Studies about *GSTM1* null genotype effect on air pollutant especially PM association with diabetes mellitus (DM).

No.	Author	Sample number	Pollutant type	Parameters measured	Result
1	Kim et al. [98]	560	PM <sub>10</sub> , ozone, and NO <sub>2</sub>	Fasting glucose, insulin, homeostatic model assessment (HOMA) index to assess insulin resistance (IR)	PM <sub>10</sub> , ozone, and NO <sub>2</sub> induced fasting plasma glucose, insulin, and HOMA associated interquartile range increase in participants with <i>GSTM1</i> null genotype compared with those with intact <i>GSTM1</i>
2	Schneider et al. [99]	20 Type 2 diabetic mellitus	PM <sub>2.5</sub>	Monocyte marker CD40 and CD80	Markers CD40 and CD80 show a stronger association with PM <sub>2.5</sub> in individuals with <i>GSTM1</i> null genotype
3	Schneider et al. [100]	22 Type 2 diabetic mellitus	PM <sub>2.5</sub>	Inflammation/coagulation parameters and blood panel	In individuals with DM with <i>GSTM1</i> null genotype, the changes in IL-6, RBC, total haemoglobin, and Mean corpuscular volume (MCV) induced by PM <sub>2.5</sub> is more prominent

associated with air pollutant exposure in individuals with *GSTM1* null genotype suggest that individuals with deletion of *GSTM1* is more prone to develop air pollutant induce cardiovascular. Interestingly, the administration of statin could modulate the *GSTM1* deletion effect associated with cardiovascular disturbance and air pollutants [70]. Those results show a potential intervention to prevent cardiovascular disturbance associated with air pollutants in individuals with *GSTM1* null genotype.

**8.3. Endocrine System.** There are only a few studies about the *GSTM1* null genotype effect on air pollution-induced endocrine system disease. Table 4 showed a summary of studies about *GSTM1* null genotype effect on air pollution-induced endocrine system disturbances.

Based on those results, *GSTM1* null genotype is an essential factor in the glucose metabolism disturbance and inflammation development in air pollutant-induced DM. Individual carrying *GSTM1* null genotype is more prone to develop glucose metabolism disturbance, and when they are DM patients, they might be easier to experience DM-related complications elicited by exposure to air pollutants.

**8.4. Nervous System.** *GSTM1* null genotype also modifies the association of air pollutants with several nervous system problems. Table 5 summarizes studies about *GSTM1* null genotype effect on air pollutant-induced nervous system diseases.

That studies showed that *GSTM1* variation could modify air pollutant effect on nervous system disturbance.

## 9. *GSTM1* Null Genotype and Antioxidant

DEP exposure to primary human bronchial epithelial cell with *GSTM1* deletion result in markedly higher IL-8 and IL-1 $\beta$  expression compared with than those on primary human bronchial epithelial cell without *GSTM1* deletion. Interestingly, antioxidants like *N*-acetyl cysteine can inhibit the DEP-induce cytokines expression in primary human bronchial epithelial cells [103]. This result showed that some substances could modify the effect of *GSTM1* deletion.

Antioxidants are essential factors for protecting the body from the deleterious effects of oxidants. The antioxidant can

be produced endogenously by endogenous enzymes, such as GSTs enzymes or exogenously by consuming antioxidants from diet. Individuals with endogenous antioxidant deficiencies, such as in *GSTM1* null genotype person will benefit from higher dietary antioxidant consumption. Consumption of antioxidant-rich diet in *GSTM1* null genotype individual has been known to prevent or reduces DNA adduct formation [104]. Antioxidant supplementation has a stronger effect on modifying the deleterious effect of ozone on asthmatic children with *GSTM1* null genotype than on asthmatic children with intact *GSTM1* genotype [78]. In hypertensive patients, the administration of kale juice results in lower DNA damage, especially in individuals with *GSTM1* null genotype [49].

Studies on smokers showed that people with *GSTM1* null genotype develop faster atherosclerosis progression than people with *GSTM1* wild type. Vitamin E supplementation seems to reduce the atherosclerosis progression better in *GSTM1* null genotype individuals [105]. Study on relation between *GSTM1* and lung cancer on smokers showed that the risk of lung cancer is higher among smokers with *GSTM1* null genotype and not receiving  $\alpha$ -tocopherol supplementation compare with those on smokers with *GSTM1* null genotype and receiving  $\alpha$ -tocopherol supplementation. However,  $\beta$ -carotene supplementation does not modify the correlation between *GSTM1* and the risk of lung cancer development [106]. Clinical study of vitamin B supplementation on healthy adults exposed to PM<sub>2.5</sub> for 2 hours showed that vitamin B supplementation could mitigate PM<sub>2.5</sub> effects on heart rate, LF power, total white blood count, and lymphocyte count [107]. Those studies suggest that antioxidant supplementation is potential way to modify the PM exposure effect on the development of system organ dysfunction in individual with *GSTM1* null genotype.

## 10. Conclusion

*GSTM1* deletion modify the effect of air pollutants, including PM, on the development of several health problems through oxidative stress modulation. Several substances, such as antioxidants, can potentially attenuate the deleterious effect of air pollutants on the body in individuals with *GSTM1* null genotype. However, further study is needed to explore the



TABLE 5: Studies about *GSTM1* null genotype effect on air pollutant-induced nervous system disturbances.

No.	Author	Sample number	Pollutant type	Parameters measured	Result
1.	Lee et al. [101]	720 pregnant women	Second-hand smoke (SHS)	Mental Development Index (MDI) and Psychomotor Development Index (PDI) in their children	MDI of children from mothers with <i>GSTM1/GSTT1</i> double deletion showed a significant negative association with cotinine level (predictor for SHS exposure)
2.	de Souza Pinhel et al. [102]	423	Pesticide exposure	Parkinson's disease (PD)	A combination of <i>GSTM1-GSTT1</i> null genotype modifies PD risk related to pesticides exposure

benefit of antioxidants supplementation to prevent development of system organ problems related to PM exposure.

### Conflicts of Interest

The author(s) declare(s) that they have no conflicts of interest.

### Acknowledgments

We would like to thank the Ministry of Research and Technology/National Research and Innovation Agency Year 2021–2022 for the basic higher education research funds provided to support this research.

### References

- [1] Who, *Diseases and Air Pollution WHO European High-Level Conference on Noncommunicable Diseases Time to Deliver: Meeting NCD Targets to Achieve*, Ashgabat, Turkmenistan, 2019.
- [2] B. Brunekreef and S. T. Holgate, "Air pollution and health," *Lancet*, vol. 360, no. 9341, pp. 1233–1242, 2002.
- [3] O. G. Aztatzi-aguilar, A. Vald'es-Arzate, Debray-Garci'a Y, E. Caldero'n-Aranda, M. Uribe-Ramirez, and L. Acosta-Saavedra, "Exposure to ambient particulate matter induces oxidative stress in lung and aorta in a size- and time-dependent manner in rats," *Toxicology Research and Application*, vol. 2, p. 239784731879485, 2018.
- [4] M. Lodovici and E. Bigagli, "Oxidative stress and air pollution exposure," *Journal of Toxicology*, vol. 2011, p. 9, 2011.
- [5] R. J. Delfino, N. Staimer, and N. D. Vaziri, "Air pollution and circulating biomarkers of oxidative stress," *Air Quality, Atmosphere & Health*, vol. 4, no. 1, pp. 37–52, 2011.
- [6] H. Sies, "Oxidative stress: oxidants and antioxidants," *Experimental Physiology*, vol. 82, no. 2, pp. 291–295, 1997.
- [7] J. D. Hayes and C. Strange, "Glutathione S-transferase polymorphisms and their biological consequences," *Pharmacology*, vol. 61, no. 3, pp. 154–166, 2000.
- [8] I. A. Yang, K. M. Fong, P. V. Zimmerman, S. T. Holgate, J. W. Holloway, and P. C. Hospital, "Genetic susceptibility to the respiratory effects of air pollution," *Thorax*, vol. 63, no. 6, pp. 555–563, 2008.
- [9] H. D. Hosgood III, S. I. Berndt, and Q. Lan, "GST genotypes and lung cancer susceptibility in Asian populations with indoor air pollution exposures: a meta-analysis," *Mutation Research*, vol. 636, no. 1–3, pp. 134–143, 2007, Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf>.
- [10] K. Xiao, Y. Wang, G. Wu, B. Fu, and Y. Zhu, "Spatiotemporal characteristics of air pollutants," *Atmosphere*, vol. 9, no. 74, 2018.
- [11] K. Adams, D. S. Greenbaum, R. Shaikh, E. A. M. Van, and A. G. Russell, "Particulate matter components, sources, and health: systematic approaches to testing effects," *Journal of the Air & Waste Management Association*, vol. 65, no. 5, pp. 544–558, 2015.
- [12] M. M. Nascimento, G. O. Rocha, and A. J. B. De, "Pesticides in fine airborne particles: from a green analysis method to atmospheric characterization and risk assessment," *Scientific Reports*, vol. 7, no. 1, p. 2267, 2017.
- [13] M. T. Chin, "Basic mechanisms for adverse cardiovascular events associated with air pollution," *Heart*, vol. 101, no. 4, pp. 253–256, 2015.
- [14] Who, *Health Effects of Particulate Matter*, pp. 2–15, WHO Regional Office for Europe, Copenhagen, Denmark, 2013.
- [15] R. D. Arias-pérez and N. A. Tabora, "Inflammatory effects of particulate matter air pollution," *Environmental Science and Pollution Research*, vol. 27, no. 34, pp. 42390–42404, 2020.
- [16] N. Li, M. Hao, R. F. Phalen, W. C. Hinds, and A. E. Nel, "Particulate air pollutants and asthma A paradigm for the role of oxidative stress in PM-induced adverse health effects," *Clinical Immunology*, vol. 109, no. 3, pp. 250–265, 2003.
- [17] Q. Sun, X. Ren, Z. Sun, and J. Duan, "The critical role of epigenetic mechanism in PM2.5-induced cardiovascular diseases," *Genes and Environment*, vol. 43, no. 1, pp. 1–8, 2021.
- [18] P. K. Mishra, N. Bunkar, R. D. Singh et al., "Comparative profiling of epigenetic modifications among individuals living in different high and low air pollution zones: a pilot study from India," *Environmental Advances*, vol. 4, p. 100052, 2021.
- [19] I. Y. Song, K. Hyo Bin, K. Hwan-Cheol, L. So Yeon, K. Mi-Jin, and H. Cho, "Particulate matter at third trimester and respiratory infection in infants, modified by *GSTM1*," *Pediatric Pulmonology*, vol. 2, pp. 1–9, 2019.
- [20] W. Zou, X. Wang, W. Hong et al., "PM2.5 induces the expression of inflammatory cytokines via the Wnt5a/Ror2 pathway in human bronchial epithelial cells," *International Journal of Chronic Obstructive Pulmonary Disease*, vol. 15, pp. 2653–2662, 2020.
- [21] A. J. Ghio, C. Kim, and R. B. Devlin, "Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers," *American Journal of Respiratory and Critical Care Medicine*, vol. 162, no. 3, pp. 981–988, 2000.
- [22] D. Tsai, N. Amyai, P. Marques-vidal, J. Wang, M. Riediker, and V. Mooser, "Effects of particulate matter on inflammatory markers in the general adult population," *Particle and Fibre Toxicology*, vol. 9, no. 24, pp. 1–9, 2012.

- [23] W. Wu, Y. Jin, and C. Carlsten, "Inflammatory health effects of indoor and outdoor particulate matter," *The Journal of Allergy and Clinical Immunology*, vol. 141, no. 3, pp. 833–844, 2018.
- [24] R. W. Atkinson, I. M. Carey, A. J. Kent, S. T. P. Van, H. R. Anderson, and D. G. Cook, "Long-term exposure to outdoor air pollution and incidence of cardiovascular diseases," *Epidemiology*, vol. 24, no. 1, pp. 44–53, 2013.
- [25] G. Cesaroni, M. Stafoggia, C. Galassi, A. Hilding, B. Hoffmann, and D. Houthuijs, "Long term exposure to ambient air pollution and incidence of acute coronary events : prospective cohort study and meta-analysis in 11 European cohorts from the ESCAPE project," *BMJ*, vol. 7412, pp. 1–16, 2014.
- [26] M. Stafoggia, G. Cesaroni, A. Peters et al., "Long-term exposure to ambient air pollution and incidence of cerebrovascular events: results from 11 European cohorts within the ESCAPE project," *Environmental Health Perspectives*, vol. 122, no. 9, pp. 919–925, 2014.
- [27] Y. H. Su, M. Wang, D. E. Brenner et al., "Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be used in the detection of colorectal cancer," *Journal of Molecular Diagnostics*, vol. 6, no. 2, pp. 101–107, 2004.
- [28] J. Schwartz, "Air pollution and blood markers of cardiovascular risk," *Environmental Health Perspectives*, vol. 109, pp. 405–409, 2001.
- [29] J. Madrigano, A. Baccarelli, R. O. Wright et al., "Air pollution, obesity, genes and cellular adhesion molecules," *Occupational and Environmental Medicine*, vol. 67, no. 5, pp. 312–317, 2010.
- [30] S. I. Yang, B. J. Kim, S. Y. Lee, K. H. Bin, C. M. Lee, and J. Yu, "Prenatal particulate matter/tobacco smoke increases infants' respiratory infections: COCOA study. allergy, asthma," *Immunologic Research*, vol. 7, no. 6, pp. 573–582, 2015.
- [31] X. Zhang, J. A. Hirota, C. Yang, and C. Carlsten, "Effect of GST variants on lung function following diesel exhaust and allergen co-exposure in a controlled human crossover study," *Free Radical Biology and Medicine*, vol. 96, pp. 385–391, 2016.
- [32] M. Kioumourtzoglou, J. D. Schwartz, M. G. Weisskopf et al., "Long-term PM2.5 exposure and neurological hospital admissions in the northeastern United States," *Environmental Health Perspectives*, vol. 124, no. 1, pp. 23–29, 2016.
- [33] I. M. Carey, H. R. Anderson, R. W. Atkinson et al., "Are noise and air pollution related to the incidence of dementia? A cohort study in London, England," *BMJ Open*, vol. 8, no. 9, p. e022404, 2018.
- [34] J. Weuve, R. C. Puett, J. Schwartz, J. D. Yanosky, F. Laden, and F. Grodstein, "Exposure to particulate air pollution and cognitive decline in older women," *Archives of Internal Medicine*, vol. 172, no. 3, pp. 219–227, 2012.
- [35] S. Y. Kim, J. K. Kim, B. Kim, A.-S. Jang, S. H. Oh, and J. H. Lee, "Effects of inhaled particulate matter on the central nervous system in mice," *Neuro Toxicology*, vol. 67, pp. 169–177, 2018.
- [36] T. L. Alderete, R. Habre, C. M. Toledo-corrall, K. Berhane, Z. Chen, and F. W. Lurmann, "Longitudinal associations between ambient air pollution with insulin sensitivity,  $\beta$ -cell function, and adiposity in Los Angeles Latino children," *Journal of Diabetes*, vol. 66, pp. 1789–1796, 2017.
- [37] R. D. Brook, X. Xu, R. L. Bard et al., "Science of the total environment reduced metabolic insulin sensitivity following sub-acute exposures to low levels of ambient fine particulate matter air pollution," *Science of the Total Environment*, vol. 448, pp. 66–71, 2013.
- [38] J. Pearson, C. Bachireddy, S. Shyamprasad, A. B. Goldfine, and J. S. Brownstein, "Association between fine particulate matter and diabetes prevalence in the U.S.," *Diabetes Care*, vol. 33, no. 10, pp. 2196–2201, 2010.
- [39] D. He, S. Wu, H. Zhao et al., "Association between particulate matter 2.5 and diabetes mellitus: a meta- analysis of cohort studies," *Journal of Diabetes Investigation*, vol. 8, no. 5, pp. 687–696, 2017.
- [40] I. J. Beverland, G. R. Cohen, M. R. Heal et al., "A comparison of short-term and long-term air pollution exposure associations with mortality in two cohorts in Scotland," *Environmental Health Perspectives*, vol. 120, no. 9, pp. 1280–1285, 2012.
- [41] S. Y. Kim, S. H. Kim, J. H. Wee, C. Min, S. M. Han, and S. Kim, "Short and long term exposure to air pollution increases the risk of ischemic heart disease," *Scientific Reports*, vol. 11, no. 1, p. 5108, 2021.
- [42] J. Song, Y. Gao, S. Hu et al., "Association of long-term exposure to PM2.5 with hypertension prevalence and blood pressure in China: a cross-sectional study," *BMJ Open*, vol. 11, no. 12, pp. 1–7, 2021.
- [43] P. Tripathi, F. Deng, A. M. Scruggs, Y. Chen, and S. K. Huang, "Variation in doses and duration of particulate matter exposure in bronchial epithelial cells results in upregulation of different genes associated with airway disorders," *Toxicology in Vitro*, vol. 51, pp. 95–105, 2018, Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958625/pdf/nihms960157.pdf>.
- [44] C. A. Pope III, A. Bhatnagar, J. P. Mccracken, W. Abplanalp, D. J. Conklin, and T. O'Toole, "Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation," *Circulation Research*, vol. 119, no. 11, pp. 1204–1214, 2016.
- [45] S. Becker, J. M. Soukup, M. I. Gilmour, and R. B. Devlin, "Stimulation of human and rat alveolar macrophages by urban air particulates: effects on oxidant radical generation and cytokine production," *Toxicology and Applied Pharmacology*, vol. 141, no. 2, pp. 637–648, 1996.
- [46] P. Møller, P. H. Danielsen, D. G. Karottki et al., "Oxidative stress and inflammation generated DNA damage by exposure to air pollution particles," *Mutation Research*, vol. 762, pp. 133–166, 2014.
- [47] V. Chiurchiù and M. MacCarrone, "Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities," *Antioxidants & Redox Signaling*, vol. 15, no. 9, pp. 2605–2641, 2011.
- [48] S. Taysi, A. S. Tascan, M. G. Ugur, and M. Demir, "Radicals, oxidative/nitrosative stress and preeclampsia," *Mini-Reviews in Medicinal Chemistry*, vol. 19, no. 3, pp. 178–193, 2019.
- [49] H. Lee, J. Han, Y. K. Park, and M. Kang, "Effects of glutathione s-transferase (GST) M1 and T1 polymorphisms on antioxidant vitamins and oxidative stress-related parameters in Korean subclinical hypertensive subjects after kale juice (*Brassica oleracea acephala*) supplementation," *Nutrition Research and Practice*, vol. 12, no. 2, pp. 118–128, 2018.
- [50] N. D. Saenen, K. Vrijens, B. G. Janssen et al., "Placental Nitrosative stress and exposure to ambient air pollution during gestation: a population study," *American Journal of Epidemiology*, vol. 184, no. 6, pp. 442–449, 2016.

- [51] T. M. Penning, M. E. Burczynski, C. Hung, K. D. Mccoull, N. T. Palackal, and L. S. Tsuruda, "Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active-quinones," *Chemical Research in Toxicology*, vol. 12, no. 1, pp. 1–18, 1999.
- [52] Y. Kumagai, T. Arimoto, M. Shinyashiki et al., "Generation of reactive oxygen species during interaction of diesel exhaust particle components with NADPH-cytochrome P450 reductase and involvement of the bioactivation in the DNA damage," *Free Radical Biology & Medicine*, vol. 22, no. 3, pp. 479–487, 1997.
- [53] M. L. Block, X. Wu, Z. Pei et al., "Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase," *The FASEB Journal*, vol. 18, no. 13, pp. 1618–1620, 2004.
- [54] J. D. Lee, Q. Cai, X. O. Shu, and S. J. Nechuta, "The role of biomarkers of oxidative stress in breast cancer risk and prognosis: a systematic review of the epidemiologic literature," *Journal of Women's Health*, vol. 26, no. 5, pp. 467–482, 2017.
- [55] H. Sies, "Oxidative stress: from basic research to clinical application," *The American Journal of Medicine*, vol. 91, suppl 3C, pp. 31–38, 1991.
- [56] J. D. Hayes, J. U. Flanagan, and I. R. Jowsey, "Glutathione transferases," *Annual Review of Pharmacology and Toxicology*, vol. 45, no. 1, pp. 51–88, 2005.
- [57] A. Oakley, "Glutathione transferases: a structural perspective," *Drug Metabolism Reviews*, vol. 43, no. 2, pp. 138–151, 2011.
- [58] D. Sheehan, G. Meade, V. M. Foley, and C. A. Dowd, "Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily," *Biochemical Society*, vol. 360, no. 1, pp. 1–16, 2001.
- [59] J. K. W. Chan, J. G. Charrier, S. D. Kodani, C. F. Vogel, S. Y. Kado, and D. S. Anderson, "Combustion-derived flame generated ultrafine soot generates reactive oxygen species and activates Nrf2 antioxidants differently in neonatal and adult rat lungs," *Particle and Fibre Toxicology*, vol. 10, no. 1, p. 1, 2013, Available from: Particle and Fibre Toxicology.
- [60] F. V. Francisqueti-ferron, A. J. T. Ferron, J. L. Garcia, C. C. V. D. A. Silva, M. R. Costa, and C. S. Gregolin, "Basic concepts on the role of nuclear factor erythroid-derived 2-like 2 (Nrf2) in age-related diseases," *International Journal of Molecular Sciences*, vol. 20, no. 13, p. 3208, 2019.
- [61] N. Allocati, M. Masulli, C. Di Ilio, and L. Federici, "Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases," *Oncogenesis*, vol. 7, no. 8, 2018.
- [62] S. Nissar, A. S. Sameer, R. Rasool, N. A. Chowdri, and F. Rashid, "Glutathione S transferases: biochemistry, polymorphism and role in colorectal carcinogenesis carcinogenesis car cinogenesis & mutagenesis," *Journal of Carcinogenesis & Mutagenesis*, vol. 8, no. 2, pp. 1–9, 2017.
- [63] S. Singh, "Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death," *Cancer Chemotherapy and Pharmacology*, vol. 75, no. 1, pp. 1–15, 2015.
- [64] M. Saitou, Y. Satta, O. Gokcumen, and T. Ishida, "Complex evolution of the GSTM gene family involves sharing of GSTM1 deletion polymorphism in humans and chimpanzees," *BCMC Genomics*, vol. 19, no. 293, pp. 1–12, 2018.
- [65] R. C. Strange, M. A. Spiteri, S. Ramachandran, and A. A. Fryer, "Glutathione S-transferase family of enzymes," *Mutation Research*, vol. 482, no. 1–2, pp. 21–26, 2001.
- [66] S. P. Kasthurinaidu, T. Ramasamy, J. Ayyavoo, D. K. Dave, and D. A. Adroja, "GST M1-T1 null allele frequency patterns in geographically assorted human populations: a phylogenetic approach," *PLoS One*, vol. 10, no. 4, pp. 1–19, 2015.
- [67] M. G. Ratna, D. A. A. Nugrahaningsih, E. N. Sholikhah, E. K. Dwianingsih, and R. G. Malueka, "Heliyon the association between PON1 and GSTM1 genetic variation with methylation of p16 gene promoter among Javanese farmers exposed to pesticides at Magelang regency, Central Java, Indonesia," *Heliyon*, vol. 6, p. e03993, 2020.
- [68] G. Nasser, T. Zahedi, and F. Mousavi-kazerooni, "Prevalence of null genotypes of glutathione S-transferase T1 (GSTT1) and M1 (GSTM1) in seven Iranian populations," *Iranian Journal of Public Health*, vol. 44, no. 12, pp. 1655–1661, 2015.
- [69] W. Nooremira, W. Rashidi, and S. A. Bakar, "Glutathione S-transferase: an overview on distribution of GSTM1 and GSTT1 polymorphisms in Malaysian and other populations," *Malaysian Journal of Medicine and Health Sciences*, vol. 15, no. SP2, pp. 85–95, 2019.
- [70] J. Schwartz, S. K. Park, M. S. O. Neill, P. S. Vokonas, D. Sparrow, and S. Weiss, "Autonomic effects of particles gene-by-drug-by-environment interaction," *American Journal of Respiratory and Critical Care Medicine*, vol. 172, no. 12, pp. 1529–1533, 2005.
- [71] P. Reddy, R. N. Naidoo, T. G. Robins et al., "GSTM1 and GSTP1 gene variants and the effect of air pollutants on lung function measures in south African children," *American Journal of Industrial Medicine*, vol. 55, no. 12, pp. 1078–1086, 2012.
- [72] I. Romieu, M. Ramirez-Aguilar, J. J. Sierra-Monge, H. Moreno-Macias, B. E. del Rio-Navarro, and G. David, "GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone," *The European Respiratory Journal*, vol. 28, no. 5, pp. 953–959, 2006.
- [73] N. E. Alexis, H. Zhou, J. C. Lay et al., "The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in humans," *The Journal of Allergy and Clinical Immunology*, vol. 124, no. 6, pp. 1222.e5–1228.e5, 2009, Available from: file:///C:/Users/micac/Dropbox/Paper final seminario materia (2020)/Paper Final de Seminarios en Ingenieria Genética/Papers/UBPREP.pdf.
- [74] M. Framptom, A. Pietropaoli, M. Dentler, D. Chalupa, E. Little, and J. Stewart, "Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1," *Inhalation Toxicology*, vol. 27, no. 2, pp. 113–119, 2015.
- [75] C. S. Kim, N. E. Alexis, A. G. Rappold et al., "Lung function and inflammatory responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours," *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 9, pp. 1215–1221, 2011.
- [76] R. Ghosh, J. Topinka, J. P. Joad, M. Dostal, R. J. Sram, and I. Hertz-Picciotto, "Air pollutants, genes and early childhood acute bronchitis," *Mutation Research*, vol. 749, no. 1–2, pp. 80–86, 2013.
- [77] L. G. Hersoug, C. Brasch-Andersen, L. L. N. Husemoen, T. Sigsgaard, and A. Linneberg, "The relationship of glutathione-S-transferases copy number variation and indoor air pollution to symptoms and markers of respiratory

- disease," *The Clinical Respiratory Journal*, vol. 6, no. 3, pp. 175–185, 2012.
- [78] I. Romieu, J. Sienra-Monge, M. Ramirez-Aguilar, H. Moreno-Macias, N. Reyes-Ruiz, and B. Estela del Rio-Navarro, "Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico city," *Thorax Journal*, vol. 59, pp. 8–10, 2004.
- [79] I. Curjuric, M. Imboden, C. Schindler et al., "HMOX1 and GST variants modify attenuation of FEF25-75% decline due to PM10 reduction," *The European Respiratory Journal*, vol. 35, no. 3, pp. 505–514, 2010.
- [80] M. C. Madden, T. Stevens, M. Case et al., "Diesel exhaust modulates ozone-induced lung function decrements in healthy human volunteers," *Particle and Fibre Toxicology*, vol. 11, p. 37, 2014.
- [81] Q. Lan, X. He, D. J. Costa et al., "Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: a case-control study in Xuan Wei, China," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 9, no. 6, pp. 605–608, 2000.
- [82] T. Dey, K. Gogoi, B. G. Unni et al., "Role of glutathione S transferase polymorphism in COPD with special reference to peoples living in the vicinity of the open cast coal mine of Assam," *PLoS One*, vol. 9, no. 5, pp. 1–8, 2014.
- [83] G. Bowatte, C. J. Lodge, A. J. Lowe, B. Erbas, M. Dennekamp, and G. B. Marks, "Do variants in GSTs modify the association between traffic air pollution and asthma in adolescence?," *International Journal of Molecular Sciences*, vol. 17, no. 4, pp. 1–13, 2016.
- [84] C. Chen, M. Arjomandi, I. B. Tager, N. Holland, and J. R. Balmes, "Effects of antioxidant enzyme polymorphisms on ozone-induced lung function changes," *The European Respiratory Journal*, vol. 30, no. 4, pp. 677–683, 2007.
- [85] E. Bergamaschi, G. De Palma, P. Mozzoni, S. Vanni, M. V. Vettori, and F. Broecker, "Polymorphism of quinone-metabolizing enzymes and susceptibility to ozone-induced acute effects," *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 6, pp. 1426–1431, 2001.
- [86] M. A. Dillon, B. Harris, M. L. Hernandez et al., "Enhancement of systemic and sputum granulocyte response to inhaled endotoxin in people with the GSTM1 null genotype," *Occupational and Environmental Medicine*, vol. 68, no. 10, pp. 783–785, 2011.
- [87] F. Castro-Giner, N. Künzli, B. Jacquemin, B. Forsberg, R. De Cid, and J. Sunyer, "Traffic-related air pollution, oxidative stress genes, and asthma (ECHRS)," *Environmental Health Perspectives*, vol. 117, no. 12, pp. 1919–1924, 2009.
- [88] J. C. Hogg and S. Van Eeden, "Pulmonary and systemic response to atmospheric pollution," *Respirology*, vol. 14, pp. 336–346, 2009.
- [89] X. Wang, W. Bao, J. Liu et al., "Inflammatory markers and risk of type 2 diabetes," *Diabetes Care*, vol. 36, no. 1, pp. 166–175, 2013.
- [90] A. Hajat, M. Allison, A. V. Diez-roux, N. S. Jenny, W. Neal, and A. A. Szpiro, "HHS public access," *Epidemiology*, vol. 26, no. 3, pp. 310–320, 2015.
- [91] T. Chahine, A. Baccarelli, A. Litonjua et al., "Particulate air pollution, oxidative stress genes, and heart rate variability in an elderly cohort," *Environmental Health Perspectives*, vol. 115, no. 11, pp. 1617–1622, 2007.
- [92] D. Meier-Girard, E. Delgado-Eckert, E. Schaffner et al., "Association of long-term exposure to traffic-related PM<sub>10</sub> with heart rate variability and heart rate dynamics in healthy subjects," *Environment International*, vol. 125, pp. 107–116, 2019.
- [93] C. Ren, S. K. Park, P. S. Vokonas et al., "Air pollution and homocysteine: more evidence that oxidative stress-related genes modify effects of particulate air pollution," *Epidemiology*, vol. 21, no. 2, pp. 198–206, 2010.
- [94] N. M. Probst-Hensch, M. Imboden, D. F. Dietrich et al., "Glutathione S-transferase polymorphisms, passive smoking, obesity and heart rate variability in nonsmokers," *Environmental Health Perspectives*, vol. 116, no. 11, pp. 1494–1499, 2008.
- [95] C. S. Sack, K. L. Jansen, K. E. Cosselman et al., "Pretreatment with antioxidants augments the acute arterial vasoconstriction caused by diesel exhaust inhalation," *American Journal of Respiratory and Critical Care Medicine*, vol. 193, no. 9, pp. 1000–1007, 2016.
- [96] J. R. Balmes, M. Arjomandi, P. A. Bromberg et al., "Ozone effects on blood biomarkers of systemic inflammation, oxidative stress, endothelial function, and thrombosis: the multi-center ozone study in older subjects (MOSES)," *PLoS One*, vol. 14, no. 9, pp. 1–22, 2019.
- [97] I. Mordukhovich, E. Wilker, H. Suh et al., "Black carbon exposure, oxidative stress genes, and blood pressure in a repeated-measures study," *Environmental Health Perspectives*, vol. 117, no. 11, pp. 1767–1772, 2009.
- [98] J. H. Kim and Y. Hong, "GSTM1, GSTT1, and GSTP1 Polymorphisms and associations between air pollutants and markers of insulin resistance in elderly Koreans," *Environmental Health Perspectives*, vol. 120, no. 10, pp. 1378–1384, 2012.
- [99] A. Schneider, L. Neas, M. C. Herbst et al., "Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals," *Environmental Health Perspectives*, vol. 116, no. 12, pp. 1666–1674, 2008.
- [100] A. Schneider, L. M. Neas, D. W. Graff, M. C. Herbst, W. E. Cascio, and M. T. Schmitt, "Association of cardiac and vascular changes with ambient PM<sub>2.5</sub> in diabetic individuals," *Particle and Fibre Toxicology*, vol. 7, no. 14, pp. 1–15, 2010.
- [101] M. Lee, M. Ha, Y. C. Hong et al., "Exposure to prenatal secondhand smoke and early neurodevelopment: mothers and Children's environmental health (MOCEH) study," *Environmental Health*, vol. 18, no. 1, pp. 1–11, 2019.
- [102] M. A. de Souza Pinhel, C. L. Sado, L. G. dos Santos, M. L. Gregório, G. S. Amorim, and G. M. da Silva Florim, "Nullity of GSTT1/GSTM1 related to pesticides is associated with Parkinson's disease," *Arquivos de Neuro-Psiquiatria*, vol. 71, no. 8, pp. 527–532, 2013.
- [103] W. Wu, D. B. Peden, R. McConnell, S. Fruin, and D. Diaz-sanchez, "Glutathione-S-transferase M1 regulation of diesel exhaust particle-induced pro-inflammatory mediator expression in normal human bronchial epithelial cells," *Particle and Fibre Toxicology*, vol. 9, no. 1, p. 31, 2012.
- [104] D. Palli, G. Masala, M. Peluso, L. Gaspari, V. Krogh, and A. Munnia, "The effects of diet on DNA bulky adduct levels are strongly modified by GSTM1 genotype: a study on 634 subjects," *Carcinogenesis*, vol. 25, no. 4, pp. 577–584, 2004.

- [105] W. F. G. De, F. J. Kok, T. J. Smilde, A. Hijmans, H. Wollersheim, and A. F. H. Stalenhoef, "Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers," *Atherosclerosis*, vol. 158, pp. 227–231, 2001.
- [106] K. Woodson, C. Stewart, M. Barrett, N. K. Bhat, J. Virtamo, and P. R. Taylor, "Effect of vitamin intervention on the relationship between GSTM1, smoking, and lung cancer risk among male smokers," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 8, pp. 965–970, 1999.
- [107] J. Zhong, L. Trevisi, B. Urch, X. Lin, M. Speck, and B. A. Coull, "B-vitamin supplementation mitigates effects of fine particles on cardiac autonomic dysfunction and inflammation: a pilot human intervention trial," *Scientific Reports*, vol. 7, pp. 1–9, 2017.